Thermo Fisher Scientific (NYSE:TMO) Rating Increased to Strong-Buy at HSBC

HSBC upgraded shares of Thermo Fisher Scientific (NYSE:TMO) from a hold rating to a strong-buy rating in a report published on Tuesday morning,Zacks reports.

A number of other research firms have also issued reports on TMO. Piper Sandler raised their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a report on Monday, July 27th. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Royal Bank Of Canada upped their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research note on Friday, July 24th. Finally, Barclays raised their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $600.32 on Tuesday. Thermo Fisher Scientific has a 1 year low of $435.27 and a 1 year high of $647.00. The company has a fifty day simple moving average of $564.35 and a 200 day simple moving average of $512.92. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The company has a market cap of $221.97 billion, a P/E ratio of 32.29, a P/E/G ratio of 2.58 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific will post 25.13 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 275 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 73,768 shares of company stock worth $44,122,820 over the last three months. 0.33% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several hedge funds and other institutional investors have recently modified their holdings of TMO. Legacy Wealth Managment LLC ID raised its stake in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after acquiring an additional 22 shares in the last quarter. Kilter Group LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth about $25,000. Allied Private Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $26,000. High Note Wealth LLC lifted its holdings in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares during the last quarter. Finally, Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at about $28,000. Institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.